Genetron Holdings Limited announced that it has entered into an exclusive agreement with Jiangsu Fosun Pharmaceutical Sales Co., Ltd. to commercialize Seq-MRD?, a molecular diagnostic assay for the detection of minimal residual disease (MRD) in patients suffering from select hematologic cancers. The partnership marks the launch of Genetron Health?s first product for hematologic cancer and MRD detection in the China market. Under the agreement, Genetron Health and Jiangsu Fosun Pharma will work exclusively together to co-market and co-promote Seq-MRD? in hematologic-focused hospitals and clinics across designated territories in China. Both parties intend to serve patients afflicted by lymphoid malignancies, including acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphoid leukemia (CLL). In China, Jiangsu Fosun Pharma employs a robust sales force of roughly 1,500 representatives to promote and sell innovative drugs that target hematologic and lymphoid malignancies, solid tumors, and others. In order to promote Seq-MRD??s clinical applications, Jiangsu Fosun Pharma will bring a sizeable, experienced, hematologic cancer focused sales force and valuable relationships with clinics, hospitals and distributors to this collaboration. Genetron Health will provide technical and commercial support to the partnership; this will include promoting scientific studies, marketing, and conducting product-related training. The Seq-MRD? assay has been optimized with Genetron?s One-step Seq technology, which enables the DNA library construction process for gene sequencing to finish with a single PCR reaction and minimizes the risks of contamination and false positive results. This simple operational feature, together with Genetron?s fully automated bioinformatics solutions, enables Seq-MRD? to achieve high throughput and accuracy, good uniformity, high cost efficiency, and fast turnaround times, when compared with traditional detection methods. To date, Seq-MRD? has been tested with thousands of samples of ALL, MM, and CLL in China.